Tofacitinib in Depression (TIDE)

Sponsor
University of Oxford
Study ID
NCT04141904
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Tofacitinib 5 MG [Xeljanz] — DRUG
    Tofacitinib 5mg capsules twice a day for 7-10 days
  • Placebo — OTHER
    Placebo capsules twice a day for 7-10 days

Study Details

This study will test whether 7-10 day administration of the anti-inflammatory drug, tofacitinib, has positive effects on people experiencing treatment-resistant depression compared to placebo.

Key Dates

First listed
Oct 28, 2019
Start date
Feb 10, 2020
Status verified
Aug 2022
Primary completion
May 23, 2022
Completion
May 23, 2022

Study Design

Enrollment
2 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Tofacitinib
    Tofacitinib 5mg capsule twice a day for 7-10 days
  • Placebo Comparator: Placebo
    Placebo capsule twice a day for 7-10 days

Primary Outcome Measure

The effects of tofacitinib on emotional processing using the Facial Expression Recognition Task (FERT) [ Time Frame: Day 7-10 of drug/placebo administration ]

Find similar trials

Nationwide
Depression trialsPsychiatry trialsMental health trialsBehavioral health trials

Related Studies